Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

March

18

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

DENVER–(BUSINESS WIRE)–Mar. 18, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating...

20

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

WESTMINSTER, Colo.–(BUSINESS WIRE)–Feb. 20, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an...

18

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

WESTMINSTER, Colo.–(BUSINESS WIRE)–Nov. 18, 2025– TriSalus Life Sciences, an oncology company integrating novel delivery technology...

13

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Reports $11.6 million in revenue, up 57% year-over-year, reflecting strong liver embolization growth Investigator-published data show...

12

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Company delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarterBroadened PEDD portfolio...

4

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

DENVER–(BUSINESS WIRE)–Jun. 4, 2025– TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI),...

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated...

7

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

– Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate...

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology...

Recent developments

News

March

18

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

February

20

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

November

18

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

November

13

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

August

12

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

June

4

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

April

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

March

7

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

December

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code